

Patient Name:

DOB:

## Remicade<sup>®</sup> (infliximab) Infusion Orders

Diagnosis (please provide ICD-10 code in	space provid	led):		
Rheumatoid Arthritis	(ICD-10)	_Ankylosing Spor	dylitis	
Psoriatic Arthritis	(ICD-10)	_Other:	(description)	
Nursing Orders:	(ICD-10)		(description)	
<ul> <li>Hold infusion and notify provide</li> </ul>	r for:			
<ul> <li>Field infusion and notify provide o Signs/symptoms of illnes</li> </ul>		nfection		
<ul> <li>O Planned/recent surgical</li> </ul>		meetion		
<ul> <li>Recent live vaccinations</li> </ul>	procedures			
<ul> <li>Measure and record weight at e</li> </ul>	ach annoint	ment		
<ul> <li>If infusion-related reaction occu</li> </ul>			Hypersensitivity Read	tion Management
Policy/Protocol as clinically indic	•		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Premedications:				
Tylenol 500 mg PO PRN Benadryl 25 mg PO PRN				
Lab Orders: CBC w/diff, CMP, ESR,				
Quantiferon TB Gold o	-		n date:	
── Other:				
Administer infliximabmg				<b>mg</b> in 250 mL
0.9% sodium chloride. Use in-line, sterile	/kg x curren	<b>t weight (</b> enic low-protein l	<b>kg) =</b> binding filter (pore size	
0.9% sodium chloride. Use in-line, sterile For doses exceed	<b>/kg x curren</b> , non-pyroge	<b>t weight (</b> enic low-protein k dilute in 500 ml 0.9	<b>kg) =</b> binding filter (pore size % sodium chloride.	e 1.2 micron or less).
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n	<b>/kg x curren</b> , non-pyroge ing 1000 mg, d earest 100 mg	<b>t weight (</b> enic low-protein k dilute in 500 ml 0.9 g per protocol. To F	<b>kg) =</b> binding filter (pore size % sodium chloride. PROHIBIT dose rounding	e 1.2 micron or less). ;, check here ( 🗌 ).
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or	<b>/kg x curren</b> , non-pyroge ing 1000 mg, d earest 100 mg infliximab-ab	<b>t weight (</b> enic low-protein k dilute in 500 ml 0.9 g per protocol. To F	<b>kg) =</b> binding filter (pore sizent % sodium chloride. PROHIBIT dose rounding bayor; If BRAND NAME N	e 1.2 micron or less). ;, check here ( 🗌 ).
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or	/kg x curren , non-pyroge ing 1000 mg, d earest 100 mg infliximab-ab eck here (	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim	<b>kg) =</b> binding filter (pore size % sodium chloride. PROHIBIT dose rounding payor; If BRAND NAME N hilar substitution.	e 1.2 micron or less). ;, check here ( 🗌 ).
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch	/kg x curren , non-pyroge ing 1000 mg, d earest 100 mg infliximab-ab eck here (	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim	<b>kg) =</b> binding filter (pore size % sodium chloride. PROHIBIT dose rounding payor; If BRAND NAME N hilar substitution.	e 1.2 micron or less). ;, check here ( 🗌 ).
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of	/kg x curren , non-pyroge ing 1000 mg, e earest 100 mg infliximab-ab eck here ( calculated fo	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum	<b>kg) =</b> binding filter (pore size % sodium chloride. PROHIBIT dose rounding payor; If BRAND NAME N hilar substitution. he infusions):	e 1.2 micron or less). , check here ( 🗌 ). /IEDICALLY NECESSARY
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated	/kg x curren e, non-pyroge ing 1000 mg, d earest 100 mg infliximab-ab eck here ( calculated for for 15 minut to max rate	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for	<b>kg) =</b> pinding filter (pore size % sodium chloride. % ROHIBIT dose rounding payor; If BRAND NAME M nilar substitution. ne infusions): e to 80 ml/hr for 15 m remainder of infusior	e 1.2 micron or less). , check here (
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e	/kg x curren , non-pyroge ing 1000 mg, d earest 100 mg infliximab-ab eck here ( calculated for for 15 minuter to max rate very rate char	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least	<b>kg) =</b> pinding filter (pore size % sodium chloride. % ROHIBIT dose rounding payor; If BRAND NAME M nilar substitution. ne infusions): e to 80 ml/hr for 15 m remainder of infusior	e 1.2 micron or less). , check here (
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if pres	/kg x curren , non-pyroge ing 1000 mg, o earest 100 mg infliximab-ab eck here ( calculated for for 15 minuted for 15 minuted to max rate very rate char viously well-	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least -tolerated):	<b>kg) =</b> pinding filter (pore size % sodium chloride. % ROHIBIT dose rounding payor; If BRAND NAME M nilar substitution. ne infusions): e to 80 ml/hr for 15 m remainder of infusior	e 1.2 micron or less). , check here (
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if prev o Infuse at 125 ml/hr (over	/kg x curren , non-pyroge ing 1000 mg, of earest 100 mg infliximab-ab eck here ( calculated for for 15 minute to max rate very rate char viously well- a period of a	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least -tolerated):	<b>kg) =</b> pinding filter (pore size % sodium chloride. % ROHIBIT dose rounding payor; If BRAND NAME M nilar substitution. ne infusions): e to 80 ml/hr for 15 m remainder of infusior	e 1.2 micron or less). , check here (
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if pre- o Infuse at 125 ml/hr (over Monitor vital signs every	/kg x curren , non-pyroge ing 1000 mg, of earest 100 mg infliximab-ab eck here ( calculated for for 15 minute to max rate very rate char viously well- a period of a	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least -tolerated):	<b>kg) =</b> pinding filter (pore size % sodium chloride. % ROHIBIT dose rounding payor; If BRAND NAME M nilar substitution. ne infusions): e to 80 ml/hr for 15 m remainder of infusior	e 1.2 micron or less). , check here (
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if prev Nonitor vital signs every Frequency (chose one):	/kg x curren , non-pyroge ing 1000 mg, d earest 100 mg, infliximab-ab eck here ( calculated for for 15 minute to max rate very rate char viously well- a period of a hour.	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least <b>-tolerated):</b> at least 2 hours).	<b>kg) =</b> binding filter (pore size % sodium chloride. PROHIBIT dose rounding payor; If BRAND NAME N hilar substitution. he infusions): e to 80 ml/hr for 15 m remainder of infusior every 30 minutes.	e 1.2 micron or less). , check here ( 🗌 ). MEDICALLY NECESSARY inutes. n.
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if pre- o Infuse at 125 ml/hr (over Monitor vital signs every	/kg x curren , non-pyroge ing 1000 mg, d earest 100 mg, infliximab-ab eck here ( calculated for for 15 minute to max rate very rate char viously well- a period of a hour.	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least <b>-tolerated):</b> at least 2 hours).	<b>kg) =</b> binding filter (pore size % sodium chloride. PROHIBIT dose rounding payor; If BRAND NAME N hilar substitution. he infusions): e to 80 ml/hr for 15 m remainder of infusior every 30 minutes.	e 1.2 micron or less). , check here (
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if prev Nonitor vital signs every Frequency (chose one):	/kg x curren , non-pyroge ing 1000 mg, of earest 100 mg, infliximab-ab leck here ( calculated for for 15 minute to max rate very rate char viously well- a period of a hour.	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least tolerated): at least 2 hours).	kg) = binding filter (pore size % sodium chloride. % ROHIBIT dose rounding payor; If BRAND NAME M hilar substitution. he infusions): e to 80 ml/hr for 15 m remainder of infusion every 30 minutes.	e 1.2 micron or less). , check here ( 🗌 ). MEDICALLY NECESSARY inutes. n.
0.9% sodium chloride. Use in-line, sterile For doses exceed Dose may be rounded by up to 15% to n May substitute biosimilar (infliximab-dyyb or ch Titrate infusion rates as follows (rates of Initial three infusions: Start infusion at 20 ml/hr May increase as tolerated Monitor vital signs with e All subsequent infusions (if prev Infuse at 125 ml/hr (over Monitor vital signs every Frequency (chose one): Weeks 0, 2, and 6, then er	/kg x curren , non-pyroge ing 1000 mg, of earest 100 mg, earest 100 mg, infliximab-ab eck here (	t weight ( enic low-protein k dilute in 500 ml 0.9 g per protocol. To F da) if required by p ) to prohibit biosim or 250 ml volum tes, then increase e of 150 ml/hr for ange and at least tolerated): at least 2 hours).	kg) = pinding filter (pore size % sodium chloride. % OHIBIT dose rounding payor; If BRAND NAME N hilar substitution. he infusions): e to 80 ml/hr for 15 m remainder of infusior every 30 minutes. Every	e 1.2 micron or less). , check here ( ). //EDICALLY NECESSARY inutes. n.

per manufacturer's instructions as necessitated by product availability.